US Pharm. 2025;50(11):23-25.

In recent years, the prevalence of obesity has rapidly increased, accompanied by an exponential rise in the incidence of type 2 diabetes mellitus. Obesity is a major risk factor for type 2 diabetes, and the two conditions frequently coexist. The term diabesity was coined to highlight the strong link between excess body weight and the development of diabetes. Over the past decade, the surge in diabetes cases has closely mirrored the sharp rise in obesity rates, underscoring a clear pathogenic relationship between the two conditions.¹

Diabesity, the convergence of the obesity and diabetes pandemics, poses significant challenges for effective disease management. Without addressing both the clinical and mechanistic complications of obesity, it is difficult to develop a rational and effective treatment strategy for diabesity.¹

Several classes of antidiabetic medications, including insulin, are associated with weight gain and may inadvertently worsen the condition. Therefore, careful selection of antidiabetic therapies is essential to achieve effective and sustainable management of diabesity.¹

The role of nonpharmacologic interventions, such as dietary modifications, physical activity, and bariatric procedures, should be strongly emphasized. The importance of appropriate and optimized management of diabesity is often overlooked by healthcare professionals, however, which can hinder effective treatment and contribute to the development of complications.¹

The primary goals of treatment are to prevent further weight gain, reduce body weight by approximately 10% from baseline within 6 months, and maintain this lower body weight over the long term.¹

This column reviews the epidemiology of diabesity, the link between obesity and diabetes, the role of pancreatic beta cells, and the impact of weight loss on disease management.

Setareh Salian is very concern about it

Source: uspharmacist